Skip to main content
Clinical Trials/EUCTR2020-005682-13-NL
EUCTR2020-005682-13-NL
Active, Not Recruiting
Phase 1

Exploratory study into age-related immunological differences related to immunogenicity in influenza vaccination and herpes zoster vaccination - INFLUENZA-SHINGRIX

Radboudumc0 sites140 target enrollmentJanuary 5, 2021

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Influenza Herpes Zoster
Sponsor
Radboudumc
Enrollment
140
Status
Active, Not Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 5, 2021
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Radboudumc

Eligibility Criteria

Inclusion Criteria

  • Age between 18\-35 years old OR age \=65 years old
  • Written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 80
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 60

Exclusion Criteria

  • Known allergy to (components of) the influenza or herpes zoster vaccine
  • Immunocompromised subjects
  • Previous herpes zoster vaccination in the last year
  • Receipt of any vaccination 1 month prior to the start of the study or plans to receive any other vaccination until the last study visit
  • Chronic use of systemic drugs other than oral contraceptives
  • Use of NSAIDS less than 4 weeks prior to the start of the study
  • Acute or active illness within two weeks prior to the start of the study
  • Pregnant, breastfeeding or planning to become pregnant within the study period

Outcomes

Primary Outcomes

Not specified

Similar Trials